Rosetta Capital, a UK-based venture capital firm, invests in health tech, deep tech, and biotech companies at the Series B and Series C stages. With over 20 years of experience, they specialize in direct secondary transactions, helping investors and corporations sell investments while providing fresh capital for growth. Rosetta Capital collaborates with company boards and management teams to enhance value and support growth through corporate partnerships, IPOs, and trade sales. They have invested in over 80 healthcare companies, including Carrick Therapeutics and MISSION Therapeutics, achieving more than 30 mergers, acquisitions, or IPO exits.
